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Abstract 
 
Background: Cognitive impairment is experienced by about 50% of patients with 
Multiple Sclerosis (MS) worldwide and affects their employment, disease management 
and quality of life in general. The Brief International Cognitive assessment for MS 
(BICAMS) is a brief, practical and potentially universal battery for cognitive 
impairment in MS patients. It consists of three tests: the Symbol Digit Modalities Test 
(SDMT), the California Verbal Learning Test-2 (CVLT-2) and the Brief Visuospatial 
Memory Test-Revised (BVMT-R). 
Objective: The objective of this study was to validate the BICAMS in Greek MS 
patients and controls.  
Methods: Forty four MS patients and seventy nine healthy control (HC) participants 
were recruited and tested. They were group matched for age, education, gender and also 
premorbid cognitive reserve. All of them completed the three tests of the BICAMS 
battery. Instead of CVLT-2, the Greek validated form (Greek Verbal Learning Test, 
GVLT), was used. In addition, cognitive reserve was assessed using the Cognitive 
Reserve Index questionnaire (CRIq) standardized for the Greek population. 
Results: Significant difference was found in the performance of the two groups in all 
tests (p<0.0001, p<0.02, p<0.009 for SDMT, GVLT and BVMT-R respectively). Test-
retest reliability was good for all the tests. Based on the criterion of 1 or more tests 
below the 5th percentile of healthy controls performance, 47% of patients were found 
impaired. 
Conclusions: The study provides validation of BICAMS in Greek population and 
therefore facilitates the use of this battery in clinical practice and in future studies of 
MS patients in Greece. 
 
 
1. Introduction 
There is increasing evidence that Multiple Sclerosis (MS), one of the most known 
inflammatory diseases of the central nervous system CNS, causes cognitive decline 
apart from physical disability (Compston and Coles, 2008). Approximately half of 
patients with MS present with cognitive impairment that negatively impacts aspects of 
everyday life (Chiaravalloti and DeLuca, 2008). This cognitive inefficiency and 
memory decline affects patient's employment, communication, disease management 
and quality of life in general (Langdon, 2011), regardless the stage or type of the 
disease (Patti et al., 2009). Cognitive deficits may be undetected at consultation 
(Romero et al., 2015). 
Various neuropsychological batteries have been proposed for the assessment of 
cognitive impairment in MS as the interest in this area has been increased over the last 
years. In 2012, an expert committee proposed the Brief International Cognitive 
Assessment for Multiple Sclerosis (BICAMS) as the tool for brief cognitive 
monitoring for MS patients in clinical settings with limited resources (Langdon et al., 
2012). The committee concluded in the use of three tests with good psychometric 
properties, that could adequately evaluate information processing speed, verbal and 
visual memory; cognitive domains that are commonly found impaired in MS. Tests 
that were brief and easy to administer, without the need of special equipment, were 
preferred. The BICAMS battery is a tool which has been validated and applied in 
many countries. The aim of the present study was to validate the BICAMS in Greek 
MS patients and controls. 
 
2. Materials and Methods 
A total of 44 MS patients (mean age 40.279.9 years, 27 females) and 79 healthy 
control (HC) participants (mean age 36.2710.6 years, 48 females) were recruited from 
January 2014 to January 2015. Healthy individuals were age, education, gender and 
premorbid cognitive reserve - matched controls. The mean years of education were 
14.174.8 for patients and 15.475.5 for HC. All patients (RRMS, SPMS and PPMS) 
were diagnosed for MS according to the 2010 revised Mc Donald criteria (Polman et 
al., 2011) and were included regardless of any Disease Modifying Treatment (DMT) 
they may have taken. Patients with Clinically Isolated Syndrome (CIS) were included 
in the MS group, as previous studies have reported cognitive impairment even in the 
initial stages of the disease (Glanz et al., 2007; Štecková et al.). Demographic data 
and disease characteristics of the patient group are presented in Table 1. All patients 
and all HC provided written informed consent for participation in the study and the 
research project has been approved by the Ethics Committee of Aristotle University of 
Thessaloniki. All patients and HC were Caucasian Greek individuals free of any 
major psychiatric illness or disease that could affect cognition (other than MS). MS 
patients had to be free of relapses or any disease progression for the last three months. 
All subjects had adequate vision and hearing ability to undergo examination with the 
BICAMS battery. Moreover, 19 MS patients and 24 HC underwent assessment with 
alternate forms of the tests three weeks after the first examination in order to assess 
test-retest reliability. This study was non-interventional and was not obligatory for 
safety data to be collected. Nevertheless, if an adverse event had occurred during the 
study, and was suspected to be associated with any pharmaceutical substance that the 
patient had received, it had to be reported to the local Health Authority. 
3. Neuropsychological Assessment 
All patients and HC underwent neuropsychological assessment using the BICAMS 
battery which includes the following tests: 
The Symbol Digit Modalities Test (SDMT) (Smith, 1982) is a measure of information 
processing speed. It consists of a series of nine symbols, each in association with a 
single digit. Participants enunciate the digit related to each symbol in a randomized 
sequence, as fast as they can, in a 90s session. The total score is derived from the 
number of correct answers. We used the SDMT alternate forms created by Benedict et 
al. (2012). These two forms are equivalent to the original version and provide good test-
retest reliability. Alternate form one was used for the assessment and alternate form two 
was used for the retest session. 
The California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) is a measure of 
verbal memory. It consists of a list of 16 words that the subject must learn. The 
procedure is repeated five times. Instead of the CVLT-II, the Greek adaptation Greek 
Verbal Learning Test (GVLT) (Vlachou et al., 2013) was used in this study. GVLT 
provides the same number of words and number of trials as used in CVLT-II. Words 
are culturally adapted for the Greek population. GVLT provides three alternate forms 
with satisfactory psychometric properties. Total score is derived from the total number 
of words recalled over five trials, just like CVLT-II recommended primary outcome for 
BICAMS battery. Form A was used for the assessment and form B for the retest session. 
The Brief Visuospatial Memory Test-Revised (BVMT-R) (Benedict, 1997) is a 
measure of visuospatial memory. The subjects are asked to remember a page with six 
designs for ten seconds. The procedure is repeated three times. Each design is scored 
with zero, one or two points, depending on accuracy and location. Total recall score is 
the sum of the individual scores of the three trials. BVMT-R comes with 6 equivalent 
alternate forms. We used form one for the assessment and form two for the retest 
session. The above procedure was performed by neurologists in the neuropsychology 
unit of the MS center of B’ Department of Neurology, AHEPA University Hospital. 
Examiners had previously attended training sessions, in order to ensure uniform 
administration, while scoring was performed by two blinded observers, in order to avoid 
interrater variability. For SDMT and BVMT-R, Instructions for administration and 
scoring, were properly translated in Greek language, back translated and checked for 
errors by two independent English speaking neuropsychologists. The BICAMS battery 
was performed in a standardized way in order to ensure stable operating conditions 
without noise or fatigue factor impact. In addition, all participants were assessed with 
the Greek adaptation of Cognitive Reserve Index questionnaire (Nucci et al., 2012; 
Maiovis et al., 2016) (CRIq) in order to quantify their cognitive reserve. It is a 
questionnaire that takes into account education, professional activity and participation 
in activities that require cognitive effort, and provides a representative result of 
cognitive reserve of the individual.  
4. Statistical analysis 
Statistical analysis was performed with the use of GraphPad Prism 5 and the SPSS 18 
software packages. To account for normality in our populations, the Shapiro–Wilk test 
was used. In cases where many identical values were identified, the Kolmogorov– 
Smirnov served as the test of choice. A one-way ANOVA between groups analysis of 
variance was conducted to explore the differences among examined population as 
measured by SDMT, GVLT and BVMT-R tests. Group differences were examined also 
with Student's t-test and measurements of the linear correlation (dependence) between 
groups were assessed using Pearson's r coefficient. These r values for test-retest 
correlation were considered adequate if > 0.70 and good if > 0.80. Participants in the 
study were divided into HC (n = 79) and MS patients (n = 44). 
 
5. Results 
Descriptive statistics for the SDMT, GVLT and BVMT-R of both groups are presented in 
Table 2. We found no significant difference between MS patients and HC in matters of 
age (40.2 ± 9.9 and 37.2 ± 10.6, respectively; p = 0.11), years of education (13.9 ± 4.2 
and 15.6 ± 5.5, respectively; p = 0.13) and gender (females 61.3% and 60.7% 
respectively). There was a statistically significant difference at the p < 0.05 level in all 
three tests of the BICAMS for the two groups. The results indicated that HC had 
significantly higher SDMT test score compared to MS patients (61.4 ± 13.1 vs 45.0 ± 
17.2, p < 0.0001, r = 0.47, d =1.07). As predicted, HC group had also higher GVLT test 
score than MS patients (60.5 ± 10.7 vs 55.5 ± 12.3, p = 0.02, r = 0.21, d = 0.43). Finally, 
HC had also higher BVMT-R test score compared to MS patients (22.1 ± 6.5 vs 18.5 ± 
8.3, p = 0.009, r = 0.23, d = 0.48). Test-retest reliability was very good for all 3 tests 
(Table 3) in both groups. The CRIq results, revealed no significant difference between the 
two groups (P value = 0.5593). There was a positive correlation between the two 
variables CRI and education years in HC (r = 0.85, p < 0.0001) and also in MS patients (r 
= 0.73, p < 0.0001). 
In order to evaluate how many MS patients were found impaired on each of the three 
components of BICAMS, we identified the 5th percentile on each performance of the HC 
group. Based on the proposed criterion of one or more tests performance below the 5th 
percentile of healthy controls performance, we found that 47% of patients presented 
cognitive dysfunction.  Table 4 summarizes the results and the estimation of impaired MS 
patients on one, two, and three tests. 
 
6. Discussion 
Evaluation of cognition in MS is necessary for appropriate rehabilitation, vocational 
counseling, and quantification of disability. Many diagnostic batteries have been used 
for this purpose in large MS centers worldwide. The most commonly used batteries of 
neuropsychological tests in MS are the Brief Repeatable Battery of 
Neuropsychological tests (BRB-N) (Rao, 1990) and also the Minimal Assessment of 
Cognitive Function in MS (MACFIMS) (Benedict et al., 2006). Although accurate, 
these batteries may be time consuming (BRB-N takes about 45 min; MACFIMS takes 
about 90 min) and therefore not suitable for everyday clinical practice, especially in 
centers without a neuropsychologist. There is a need for a brief cognitive assessment 
tool with adequate reliability, validity, specificity and sensitivity, which can provide 
widespread, accurate cognitive evaluations (Langdon et al., 2012). The BICAMS 
battery can be used in small MS centers, without staff trained in neuropsychology 
(Goverover et al., 2016). After reaching international validation (Benedict et al., 
2012), it may contribute in the progress of understanding the natural history of MS. It 
may also assist in the disease prognosis, management and treatment decisions by 
informing physicians about the memory and mental state of the patient. 
Previous studies about cognitive dysfunction in MS, have taken into account age, 
education and gender in order to evaluate patients' performance. In the present study, 
we felt that including patient's lifestyle, would provide more insight about their 
cognitive reserve, therefore we also included the Cognitive Reserve Index 
questionnaire (CRIq). This is a new standardized tool for cognitive reserve 
assessment. CRIq can be used in both experimental research and in clinical practice, 
and could be taken into consideration in the validation of many psychometric tests 
(Nucci et al., 2012; Maiovis et al., 2016). 
According to the results and the statistical analysis of the current study, MS patients 
performed worse in all three tests of BICAMS battery. Particularly, in SDMT and 
BVMT-R the patients exhibited the lowest scores. The findings are in accordance with 
previous studies (Dusankova et al., 2012; Sandi et al., 2015) where SDMT and 
BVMT-R presented better sensitivity in discriminating patients from healthy controls. 
In this study, 47% of our patients exhibited cognitive dysfunction, thus indicating a 
slightly lower percentage from other studies (Dusankova et al., 2012;  O’Connell  et 
al., 2015), presumably due to the inclusion of CIS patients. Indeed, such an 
interpretation may be easily speculated particularly on the basis of previous studies, 
where 47.5% of Greek MS and CIS patients, exhibited cognitive dysfunction (Potagas 
et al., 2008), whereas similar impairment was noticed in up to 53.75% of MS patients, 
none of which was a CIS case (Papathanasiou et al., 2014). Nevertheless, we 
anticipate more enriched and solid results as this study progresses and the number of 
participants is increased. 
Unfortunately, we were not able to determine the relation of BICAMS to employment 
in Greece, since, the overall increase of unemployment due to the austerity measures 
and financial deterioration in the country makes hard to identify whether MS-related 
cognitive impairment may, per se, have a clear impact on unemployment among 
patients. 
Moreover, the use of BICAMS in everyday clinical practice, might potentially aid to 
the disease and drug management in general, disease prognosis and treatment 
decisions. Relevant prospective studies would largely clarify such a possibility. 
Nevertheless, such a brief cognitive tool, could help physicians detect cognitive 
deficits as early as possible, in order to ensure more detailed evaluation and proper 
management of long term cognitive decline for all MS patients (Benedict, 2005). 
However, although this battery could provide access for all MS centers to cognitive 
study and management (Dusankova et al., 2012), it may by no means replace more 
comprehensive evaluation of the cognitive function (Goretti et al., 2014). BICAMS 
should be used as a helpful instrument for both big and small MS centers in order to 
maximize the international assessment of cognitive impairment (Eshaghi et al., 2012; 
Morrow et al., 2010; Spedo et al., 2015). This study for the Greek validation of the 
BICAMS highlights the scale as a reliable and valid short cognitive tool that can be 
used for evaluation of people with MS in Greece. 
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Table 1. Descriptive data of the patient group. 
Disease 
type 
n females Mean age Median 
EDSS (min-
max) 
Mean 
years 
from 
diagnosis 
Mean 
Years of 
education 
CIS    3 66.6% 21.3 ± 3.2 2.0 (1.0-2.0) 1.6 ± 0.5 13.6 ± 1.5 
RRMS  34 61.7% 40.6 ± 8.7 3.0 (1.5-5.0) 9.6 ± 3.7 14.9 ± 3.7 
PPMS     3 66.6% 47.3 ± 5.5 4.0 (3.0-4.5) 6.0 ± 2.6 13.0 ± 3.6 
SPMS 4 50.0% 47.0 ± 8.7 5.5 (4.0-6.0) 7.5 ± 3.7 14.7 ± 5.9 
Total 44 61.3% 40.2 ± 9.9 3.5 (1.0-6.0) 9.1 ± 4.1 14.1 ± 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Group characteristics and BICAMS performance 
  Patients Healthy controls P value 
Age 40.2 ± 9.9      37.2 ± 10.6  0.11 
Education 13.9 ± 4.2      15.6 ± 5.5       0.13 
SDMT 45.0 ± 17.2      61.4 ± 13.1    <0.0001 
GVLT 55.5 ± 12.3      60.0 ± 10.7       0.02 
BVMT-R 18.5 ± 8.3      22.1 ± 6.5       0.009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. BICAMS Test-retest reliability assessment 
Test/Group   r        p 
SDMT/HC 0.97 <0.0001 
GVLT/HC 0.88 <0.0001 
BVMT-R/HC  0.94 <0.0001 
SDMT/MS 
GVLT/MS 
BVMT-R/MS 
0.96 
0.97 
0.95 
<0.0001 
<0.0001 
<0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Prevalence of cognitive impairment in MS patients according to the 5th 
percentile value of HC on BICAMS tests. 
 
5th Percentile value for 
HC on each test 
Percentage of patients with 
lower score 
SDMT 40 43 % 
GVLT 43 20 % 
BVMT-R 13 22 % 
 MS patients impaired on tests of BICAMS 
On 1 test 47  % 
On 2 tests 25  % 
On 3 tests 11 % 
 
 
 
